Rank

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

OMIM: 603499

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

RANK is the acronym for "Receptor Activator of NF-κB". RANK is a transmembrane protein from the family of tumor necrosis factors (TNF), which is found in mammals and is expressed by maturation and adult osteoclasts. RANK is encoded by the TNFRSF11A gene.

General informationThis section has been translated automatically.

RANK, together with its ligand RANKL (Receptor Activator of NF-κB ligand) and another regulatory protein osteoprotegerin (OPG), plays a key role in the regulation of bone remodeling.

Note(s)This section has been translated automatically.

For further details see RANKL below

LiteratureThis section has been translated automatically.

  1. Hanada R et al (2011) RANKL/RANKbeyond bones. Journal of Molecular Medicine 89: 647-656.
  2. Hofbauer LC (2010) Importance of the RANK / RANKL / OPG signaling pathway for bone metabolism. Osteology 19: 354-357.
  3. Kartsogiannis V et al.(1999) Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25, 525-34.
  4. Keck AV et al (2003) Bone metabolism in malignant diseases. Journal for Mineral Metabolism (2003) 10:6-11
  5. Luo J et al (2016) LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nature Medicine 22, 539-546.
  6. Owen S et al (2013) Expression profile of receptor activator of nuclear-κb (rank), rank ligand (rankl) and osteoprotegerin (OPG) in breast cancer. Anticancer Research 33, 199-206.
  7. Teitelbaum SL (2006) Osteoclasts; culprits in inflammatory osteolysis. Arthritis research and therapy 8: 201-206.
  8. Zhang X et al (2017) RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src. OncoTargets and Therapy 10: 73-83.

Authors

Last updated on: 29.10.2020